512 related articles for article (PubMed ID: 27344341)
1. Modulation of innate immunity in the tumor microenvironment.
Gonzalez-Gugel E; Saxena M; Bhardwaj N
Cancer Immunol Immunother; 2016 Oct; 65(10):1261-8. PubMed ID: 27344341
[TBL] [Abstract][Full Text] [Related]
2. Tim-3 and its role in regulating anti-tumor immunity.
Das M; Zhu C; Kuchroo VK
Immunol Rev; 2017 Mar; 276(1):97-111. PubMed ID: 28258697
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
4. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.
Prokopi A; Tripp CH; Tummers B; Hornsteiner F; Spoeck S; Crawford JC; Clements DR; Efremova M; Hutter K; Bellmann L; Cappellano G; Cadilha BL; Kobold S; Boon L; Ortner D; Trajanoski Z; Chen S; de Gruijl TD; Idoyaga J; Green DR; Stoitzner P
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408092
[TBL] [Abstract][Full Text] [Related]
5. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
6. Characterization and Manipulation of the Crosstalk Between Dendritic and Natural Killer Cells Within the Tumor Microenvironment.
Jacobs B; Gebel V; Heger L; Grèze V; Schild H; Dudziak D; Ullrich E
Front Immunol; 2021; 12():670540. PubMed ID: 34054844
[TBL] [Abstract][Full Text] [Related]
7. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.
da Silva IP; Gallois A; Jimenez-Baranda S; Khan S; Anderson AC; Kuchroo VK; Osman I; Bhardwaj N
Cancer Immunol Res; 2014 May; 2(5):410-22. PubMed ID: 24795354
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.
Pirozyan MR; McGuire HM; Emran AA; Tseng HY; Tiffen JC; Lee JH; Carlino MS; Menzies AM; Long GV; Scolyer RA; Fazekas de St Groth B; Hersey P
Front Immunol; 2020; 11():372. PubMed ID: 32210968
[TBL] [Abstract][Full Text] [Related]
9. Influence of Galectin-9 Treatment on the Phenotype and Function of NK-92MI Cells in the Presence of Different Serum Supplements.
Meggyes M; Nagy DU; Balassa T; Godony K; Peterfalvi A; Szereday L; Polgar B
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439744
[TBL] [Abstract][Full Text] [Related]
10. TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma.
Damo M; Wilson DS; Simeoni E; Hubbell JA
Sci Rep; 2015 Dec; 5():17622. PubMed ID: 26631690
[TBL] [Abstract][Full Text] [Related]
11. NK cell expression of Tim-3: First impressions matter.
So EC; Khaladj-Ghom A; Ji Y; Amin J; Song Y; Burch E; Zhou H; Sun H; Chen S; Bentzen S; Hertzano R; Zhang X; Strome SE
Immunobiology; 2019 May; 224(3):362-370. PubMed ID: 30876792
[TBL] [Abstract][Full Text] [Related]
12. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.
Barry KC; Hsu J; Broz ML; Cueto FJ; Binnewies M; Combes AJ; Nelson AE; Loo K; Kumar R; Rosenblum MD; Alvarado MD; Wolf DM; Bogunovic D; Bhardwaj N; Daud AI; Ha PK; Ryan WR; Pollack JL; Samad B; Asthana S; Chan V; Krummel MF
Nat Med; 2018 Aug; 24(8):1178-1191. PubMed ID: 29942093
[TBL] [Abstract][Full Text] [Related]
13. Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer.
Bödder J; Zahan T; van Slooten R; Schreibelt G; de Vries IJM; Flórez-Grau G
Front Immunol; 2020; 11():631713. PubMed ID: 33679726
[TBL] [Abstract][Full Text] [Related]
14. Delivery of TLR7 agonist to monocytes and dendritic cells by DCIR targeted liposomes induces robust production of anti-cancer cytokines.
Klauber TCB; Laursen JM; Zucker D; Brix S; Jensen SS; Andresen TL
Acta Biomater; 2017 Apr; 53():367-377. PubMed ID: 28153581
[TBL] [Abstract][Full Text] [Related]
15. Bidirectional interactions of NK cells and dendritic cells in immunotherapy: current and future perspective.
Mahmood S; Upreti D; Sow I; Amari A; Nandagopal S; Kung SK
Immunotherapy; 2015; 7(3):301-8. PubMed ID: 25804481
[TBL] [Abstract][Full Text] [Related]
16. Innate immunity in cutaneous melanoma.
Mignogna C; Scali E; Camastra C; Presta I; Zeppa P; Barni T; Donato G; Bottoni U; Di Vito A
Clin Exp Dermatol; 2017 Apr; 42(3):243-250. PubMed ID: 28052512
[TBL] [Abstract][Full Text] [Related]
17. Melanoma and lymphoma rejection associated with eosinophil infiltration upon intratumoral injection of dendritic and NK/LAK cells.
Capobianco A; Manfredi AA; Monno A; Rovere-Querini P; Rugarli C
J Immunother; 2008 Jun; 31(5):458-65. PubMed ID: 18463539
[TBL] [Abstract][Full Text] [Related]
18. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L
Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759
[TBL] [Abstract][Full Text] [Related]
19. Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function.
Degos C; Heinemann M; Barrou J; Boucherit N; Lambaudie E; Savina A; Gorvel L; Olive D
Front Immunol; 2019; 10():877. PubMed ID: 31105699
[TBL] [Abstract][Full Text] [Related]
20. The interaction of NK cells and dendritic cells in the tumor environment: how to enforce NK cell & DC action under immunosuppressive conditions?
Jacobs B; Ullrich E
Curr Med Chem; 2012; 19(12):1771-9. PubMed ID: 22414086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
